Osteoporosis in neurodegeneration

Journal of Trace Elements in Medicine and Biology

Volumn 28, Issue 4, 2014, Pages 418-421

  Roos, Per M ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Metals; Neurodegeneration; Osteoporosis

Indexed keywords

ALUMINUM; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ARSENIC; CADMIUM; CALCIUM; HYDROXYAPATITE; LEAD;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BONE DENSITY; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; HUMAN; INORGANIC CHEMISTRY; MULTIPLE SCLEROSIS; NEUROTOXICITY; OSTEOPOROSIS; PARKINSON DISEASE; PATHOGENESIS;

EID: 84940166156     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2014.08.010     Document Type: Article

References (49)

1. Kanis J.A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report, WHO Study Group. Osteoporos Int 1994, 4:368-381.
2. Aaseth J., Boivin G., Andersen O. Osteoporosis and trace elements - an overview. J Trace Elem Med Biol 2012, 26:149-152.
3. Cooper C., Cole Z.A., Holroyd C.R., Earl S.C., Harvey N.C., Dennison E.M., et al. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 2011, 22:1277-1288.
4. Johnell O., Gullberg B., Allander E., Kanis J.A., Group M.S. The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporos Int 1992, 2:298-302.
5. Akesson A., Bjellerup P., Lundh T., Lidfeldt J., Nerbrand C., Samsioe G., et al. Cadmium-induced effects on bone in a population-based study of women. Environm Health Perspect 2006, 114:830-834.
6. Wirdefeldt K., Adami H.O., Cole P., Trichopoulos D., Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 2011, 26(Suppl. 1):S1-S58.
7. Trapp B.D., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu Rev Neurosci 2008, 31:247-269.
8. Fang F., Valdimarsdottir U., Bellocco R., Ronnevi L.O., Sparen P., Fall K., et al. Amyotrophic lateral sclerosis in Sweden, 1991-2005. Arch Neurol 2009, 66:515-519.
9. Rocca W.A., Petersen R.C., Knopman D.S., Hebert L.E., Evans D.A., Hall K.S., et al. Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimers Dement 2011, 7:80-93.
10. Cannon J.R., Greenamyre J.T. The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol Sci 2011, 124:225-250.
11. Rey C., Combes C., Drouet C., Glimcher M.J. Bone mineral: update on chemical composition and structure. Osteoporos Int 2009, 20:1013-1021.
12. Zhu G., Wang H., Shi Y., Weng S., Jin T., Kong Q., et al. Environmental cadmium exposure and forearm bone density. Biometals 2004, 17:499-503.
13. Jaworowski Z., Barbalat F., Blain C., Peyre E. Heavy metals in human and animal bones from ancient and contemporary France. Sci Total Environ 1985, 43:103-126.
14. Jin T., Nordberg G., Ye T., Bo M., Wang H., Zhu G., et al. Osteoporosis and renal dysfunction in a general population exposed to cadmium in China. Environ Res 2004, 96:353-359.
15. Squitti R. Metals in Alzheimer's disease: a systemic perspective. Front Biosci 2012, 17:451-472.
16. Brewer G.J. Alzheimer's disease causation by copper toxicity and treatment with zinc. Front Aging Neurosci 2014, 6:92.
17. Ayton S., Lei P., Bush A.I. Metallostasis in Alzheimer's disease. Free Radic Biol Med 2013, 62:76-89.
18. Dusek P., Roos P.M., Litwin T., Schneider S.A., Flaten T.P., Aaseth J. The neurotoxicity of iron, copper and manganese in Parkinson's and Wilson's diseases. J Trace Elem Med Biol 2014, (In press). 10.1016/j.jtemb.2014.05.007.
19. Miotto M.C., Rodriguez E.E., Valiente-Gabioud A.A., Torres-Monserrat V., Binolfi A., Quintanar L., et al. Site-specific copper-catalyzed oxidation of alpha-synuclein: tightening the link between metal binding and protein oxidative damage in Parkinson's disease. Inorg Chem 2014, 53:4350-4358.
20. Roos P.M., Vesterberg O., Syversen T., Flaten T.P., Nordberg M. Metal concentrations in cerebrospinal fluid and blood plasma from patients with amyotrophic lateral sclerosis. Biol Trace Elem Res 2013, 151:159-170.
21. Kwan J.Y., Jeong S.Y., Van Gelderen P., Deng H.X., Quezado M.M., Danielian L.E., et al. Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 tesla MRI and pathology. PLoS ONE 2012, 7:e35241.
22. Roos P.M. Studies on metals in motor neuron disease 2013, 1-79. Institute of Environmental Medicine, Karolinska Institutet, Stockholm.
23. LeVine S.M., Bilgen M., Lynch S.G. Iron accumulation in multiple sclerosis: an early pathogenic event. Expert Rev Neurother 2013, 13:247-250.
24. Singh A.V., Zamboni P. Anomalous venous blood flow and iron deposition in multiple sclerosis. J Cereb Blood Flow Metab 2009, 29:1867-1878.
25. Zamboni P. The big idea: iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis. J R Soc Med 2006, 99:589-593.
26. Mehta V. Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PLOS ONE 2013, 8:e57573.
27. Exley C., Mamutse G., Korchazhkina O., Pye E., Strekopytov S., Polwart A., et al. Elevated urinary excretion of aluminium and iron in multiple sclerosis. Mult Scler 2006, 12:533-540.
28. Zheng W., Fu S.X., Dydak U., Cowan D.M. Biomarkers of manganese intoxication. Neurotoxicology 2011, 32:1-8.
29. Zheng W., Aschner M., Ghersi-Egea J.F. Brain barrier systems: a new frontier in metal neurotoxicological research. Toxicol Appl Pharmacol 2003, 192:1-11.
30. O'Neal S.L., Hong L., Fu S., Jiang W., Jones A., Nie L.H., et al. Manganese accumulation in bone following chronic exposure in rats: steady-state concentration and half-life in bone. Toxicol Lett 2014, 229:93-100.
31. Abbott N.J., Patabendige A.A., Dolman D.E., Yusof S.R., Begley D.J. Structure and function of the blood-brain barrier. Neurobiol Dis 2010, 37:13-25.
32. Zheng W. Toxicology of choroid plexus: special reference to metal-induced neurotoxicities. Microsc Res Tech 2001, 52:89-103.
33. Raglione L.M., Sorbi S., Nacmias B. Osteoporosis and Parkinson's disease. Clin Cases Miner Bone Metab 2011, 8:16-18.
34. Fink H.A., Kuskowski M.A., Taylor B.C., Schousboe J.T., Orwoll E.S., Ensrud K.E., et al. Association of Parkinson's disease with accelerated bone loss, fractures and mortality in older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int 2008, 19:1277-1282.
35. Yamada T., Kachi T., Ando K. Osteoporosis and fractures in Parkinson's disease. Nihon Ronen Igakkai zasshi Jpn J Geriatr 1995, 32:637-640.
36. Zhou R., Deng J., Zhang M., Zhou H.D., Wang Y.J. Association between bone mineral density and the risk of Alzheimer's disease. J Alzheimers Dis 2011, 24:101-108.
37. Chang K.H., Chung C.J., Lin C.L., Sung F.C., Wu T.N., Kao C.H. Increased risk of dementia in patients with osteoporosis: a population-based retrospective cohort analysis. Age 2014, 36:967-975.
38. Roos P.M., Vesterberg O., Nordberg M. Inclusion body myositis in Alzheimer's disease. Acta Neurol Scand 2011, 124:215-217.
39. Li S., Liu B., Zhang L., Rong L. Amyloid beta peptide is elevated in osteoporotic bone tissues and enhances osteoclast function. Bone 2014, 61:164-175.
40. Sato Y., Honda Y., Asoh T., Kikuyama M., Oizumi K. Hypovitaminosis D and decreased bone mineral density in amyotrophic lateral sclerosis. Eur Neurol 1997, 37:225-229.
41. Mallette L.E., Patten B., Cook J.D., Engel W.K. Calcium metabolism in amyotrophic lateral sclerosis. Dis Nerv Syst 1977, 38:457-461.
42. Yanagihara R., Garruto R.M., Gajdusek D.C., Tomita A., Uchikawa T., Konagaya Y., et al. Calcium and vitamin D metabolism in Guamanian Chamorros with amyotrophic lateral sclerosis and parkinsonism-dementia. Ann Neurol 1984, 15:42-48.
43. Hearn A.P., Silber E. Osteoporosis in multiple sclerosis. Mult Scler 2010, 16:1031-1043.
44. Gupta S., Ahsan I., Mahfooz N., Abdelhamid N., Ramanathan M., Weinstock-Guttman B. Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions. CNS Drugs 2014, 28(8):731-742.
45. Weinstock-Guttman B., Gallagher E., Baier M., Green L., Feichter J., Patrick K., et al. Risk of bone loss in men with multiple sclerosis. Mult Scler 2004, 10(2):170-175.
46. Chen X., Wang K., Wang Z., Gan C., He P., Liang Y., et al. Effects of lead and cadmium co-exposure on bone mineral density in a Chinese population. Bone 2014, 63:76-80.
47. Kjellstrom T. Mechanism and epidemiology of bone effects of cadmium 1992, 301-310. IARC Scientific Publications.
48. Li X., Hu C., Zhu Y., Sun H., Li Y., Zhang Z. Effects of aluminum exposure on bone mineral density, mineral, and trace elements in rats. Biol Trace Elem Res 2011, 143:378-385.
49. Wu C.T., Lu T.Y., Chan D.C., Tsai K.S., Yang R.S., Liu S.H. Effects of arsenic on osteoblast differentiation in vitro and on bone mineral density and microstructure in rats. Environ Health Perspect 2014, 122:559-565.